CoraLite®594-conjugated GSDMD Monoclonal antibody

GSDMD Monoclonal Antibody for IF/ICC

Host / Isotype

Mouse / IgG2a

Reactivity

human

Applications

IF/ICC

Conjugate

CoraLite®594 Fluorescent Dye

CloneNo.

2E6C7

Cat no : CL594-66387

Synonyms

DF5L, DFNA5L, FKSG10, FLJ12150, gasdermin D, GSDMD, GSDMDC1


☆大好評トライアルサイズ ¥20,000~! >>> 一次抗体特別価格キャンペーン開催中!


Tested Applications

Positive IF/ICC detected inHeLa cells

Recommended dilution

ApplicationDilution
Immunofluorescence (IF)/ICCIF/ICC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

CL594-66387 targets GSDMD in IF/ICC applications and shows reactivity with human samples.

Tested Reactivity human
Host / Isotype Mouse / IgG2a
Class Monoclonal
Type Antibody
Immunogen GSDMD fusion protein Ag16827 相同性解析による交差性が予測される生物種
Full Name gasdermin D
Calculated molecular weight 484 aa, 53 kDa
Observed molecular weight 47-53 kDa
GenBank accession numberBC008904
Gene symbol GSDMD
Gene ID (NCBI) 79792
RRIDAB_2883574
Conjugate CoraLite®594 Fluorescent Dye
Excitation/Emission maxima wavelengths588 nm / 604 nm
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
Storage ConditionsStore at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

GSDMD is a member of the gasdermin family. Members of this family appear to play a role in regulation of epithelial proliferation. GSDMD has been suggested to act as a tumor suppressor. Recently, GSDMD is identified as a new component of inflammasomes, and it is an executor of pyroptosis and required for interleukin-1β secretion. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death.

Protocols

Product Specific Protocols
IF protocol for CL594 GSDMD antibody CL594-66387Download protocol
Standard Protocols
Click here to view our Standard Protocols